FutureChem Co.Ltd (220100) - Net Assets
Based on the latest financial reports, FutureChem Co.Ltd (220100) has net assets worth ₩50.88 Billion KRW (≈ $34.48 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩70.28 Billion ≈ $47.63 Million USD) and total liabilities (₩19.40 Billion ≈ $13.15 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check FutureChem Co.Ltd tangible equity quality to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩50.88 Billion |
| % of Total Assets | 72.4% |
| Annual Growth Rate | 7.05% |
| 5-Year Change | 25.38% |
| 10-Year Change | N/A |
| Growth Volatility | 100.64 |
FutureChem Co.Ltd - Net Assets Trend (2016–2024)
This chart illustrates how FutureChem Co.Ltd's net assets have evolved over time, based on quarterly financial data. See FutureChem Co.Ltd (220100) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for FutureChem Co.Ltd (2016–2024)
The table below shows the annual net assets of FutureChem Co.Ltd from 2016 to 2024. For live valuation and market cap data, see FutureChem Co.Ltd (220100) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩54.38 Billion ≈ $36.85 Million |
-14.92% |
| 2023-12-31 | ₩63.91 Billion ≈ $43.31 Million |
-8.87% |
| 2022-12-31 | ₩70.14 Billion ≈ $47.53 Million |
+33.05% |
| 2021-12-31 | ₩52.72 Billion ≈ $35.72 Million |
+21.54% |
| 2020-12-31 | ₩43.37 Billion ≈ $29.39 Million |
+288.50% |
| 2019-12-31 | ₩11.16 Billion ≈ $7.57 Million |
-32.16% |
| 2018-12-31 | ₩16.46 Billion ≈ $11.15 Million |
-39.50% |
| 2017-12-31 | ₩27.20 Billion ≈ $18.43 Million |
-13.74% |
| 2016-12-31 | ₩31.53 Billion ≈ $21.37 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to FutureChem Co.Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2178402253000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | ₩11.05 Billion | 20.32% |
| Other Components | ₩121.76 Billion | 223.91% |
| Total Equity | ₩54.38 Billion | 100.00% |
FutureChem Co.Ltd Competitors by Market Cap
The table below lists competitors of FutureChem Co.Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
La Française de l'Energie S.A.
PA:FDE
|
$174.61 Million |
|
Castles Technology Co Ltd
TW:5258
|
$174.69 Million |
|
Sea Sonic Electronics Co Ltd
TWO:6203
|
$174.72 Million |
|
Paik Kwang Ind
KO:001340
|
$174.73 Million |
|
SAMG Entertainment Co. Ltd.
KQ:419530
|
$174.60 Million |
|
Gencor Industries Inc
NYSE MKT:GENC
|
$174.59 Million |
|
Crown Reserve Acquisition Corp. I Class A Ordinary Shares
NASDAQ:CRAC
|
$174.48 Million |
|
Nusatrip Incorporated Common Stock
NASDAQ:NUTR
|
$174.41 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in FutureChem Co.Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 63,769,338,090 to 54,379,648,010, a change of -9,389,690,080 (-14.7%).
- Net loss of 9,417,583,150 reduced equity.
- Share repurchases of 6,499,866,250 reduced equity.
- New share issuances of 6,499,866,250 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-9.42 Billion | -17.32% |
| Share Repurchases | ₩6.50 Billion | -11.95% |
| Share Issuances | ₩6.50 Billion | +11.95% |
| Other Changes | ₩27.89 Million | +0.05% |
| Total Change | ₩- | -14.72% |
Book Value vs Market Value Analysis
This analysis compares FutureChem Co.Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 3.03x to 4.74x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩3841.87 | ₩11660.00 | x |
| 2017-12-31 | ₩3314.02 | ₩11660.00 | x |
| 2018-12-31 | ₩1960.55 | ₩11660.00 | x |
| 2019-12-31 | ₩1330.13 | ₩11660.00 | x |
| 2020-12-31 | ₩3186.16 | ₩11660.00 | x |
| 2021-12-31 | ₩2728.67 | ₩11660.00 | x |
| 2022-12-31 | ₩3173.99 | ₩11660.00 | x |
| 2023-12-31 | ₩2885.89 | ₩11660.00 | x |
| 2024-12-31 | ₩2460.96 | ₩11660.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently FutureChem Co.Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -17.32%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -54.46%
- • Asset Turnover: 0.23x
- • Equity Multiplier: 1.37x
- Recent ROE (-17.32%) is above the historical average (-36.82%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -86.53% | -1678.83% | 0.05x | 1.05x | ₩-30.44 Billion |
| 2017 | -16.51% | -149.77% | 0.08x | 1.32x | ₩-7.21 Billion |
| 2018 | -72.73% | -212.38% | 0.09x | 3.89x | ₩-13.61 Billion |
| 2019 | -48.08% | -65.73% | 0.13x | 5.66x | ₩-6.48 Billion |
| 2020 | -53.26% | -209.76% | 0.13x | 1.90x | ₩-27.44 Billion |
| 2021 | -6.49% | -28.93% | 0.15x | 1.46x | ₩-8.69 Billion |
| 2022 | -19.90% | -111.02% | 0.14x | 1.26x | ₩-20.97 Billion |
| 2023 | -10.52% | -48.03% | 0.19x | 1.14x | ₩-13.09 Billion |
| 2024 | -17.32% | -54.46% | 0.23x | 1.37x | ₩-14.86 Billion |
Industry Comparison
This section compares FutureChem Co.Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $329,362,045,253
- Average return on equity (ROE) among peers: 3.99%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| FutureChem Co.Ltd (220100) | ₩50.88 Billion | -86.53% | 0.38x | $174.61 Million |
| Dongwha Pharm.Co.Ltd (000020) | $297.40 Billion | 3.39% | 0.25x | $97.49 Million |
| Yuhan Corp. (000100) | $519.03 Billion | 9.81% | 0.47x | $3.90 Billion |
| Yuhan Corp Preferred (000105) | $1.65 Trillion | 3.48% | 0.32x | $51.83 Million |
| Yuyu Pharma (000220) | $128.69 Billion | -1.72% | 0.50x | $43.48 Million |
| Yuyu Pharma Inc (000225) | $120.36 Billion | -5.97% | 0.65x | $14.47 Million |
| Yuyu Pharma Inc (000227) | $86.87 Billion | 4.63% | 0.56x | $42.09 Million |
| Ildong Holdings Co Ltd (000230) | $55.81 Billion | 8.24% | 2.38x | $53.57 Million |
| Samil Pharm (000520) | $54.41 Billion | 1.08% | 0.83x | $101.43 Million |
| Donga Socio Holdings (000640) | $266.72 Billion | 7.48% | 1.59x | $367.37 Million |
| Jw Pharmac (001060) | $112.60 Billion | 9.51% | 2.66x | $416.42 Million |
About FutureChem Co.Ltd
FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more